PeterLabs Holdings Bhd
PeterLabs Holdings Berhad, an investment holding company, engages in manufacturing, distribution, trading, and export of animal health and nutrition products in Malaysia and internationally. The company operates through three segments: Manufacturing, Trading, and Others. It offers biosecurity products and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceutic… Read more
PeterLabs Holdings Bhd (0171) - Net Assets
Latest net assets as of September 2025: RM78.60 Million MYR
Based on the latest financial reports, PeterLabs Holdings Bhd (0171) has net assets worth RM78.60 Million MYR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RM100.31 Million) and total liabilities (RM21.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RM78.60 Million |
| % of Total Assets | 78.36% |
| Annual Growth Rate | 7.84% |
| 5-Year Change | 31.84% |
| 10-Year Change | N/A |
| Growth Volatility | 7.41 |
PeterLabs Holdings Bhd - Net Assets Trend (2015–2024)
This chart illustrates how PeterLabs Holdings Bhd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PeterLabs Holdings Bhd (2015–2024)
The table below shows the annual net assets of PeterLabs Holdings Bhd from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | RM76.94 Million | +1.56% |
| 2023-12-31 | RM75.76 Million | +1.86% |
| 2022-12-31 | RM74.37 Million | +2.70% |
| 2021-12-31 | RM72.42 Million | +24.09% |
| 2020-12-31 | RM58.36 Million | +11.22% |
| 2019-12-31 | RM52.47 Million | +8.72% |
| 2018-12-31 | RM48.26 Million | +5.51% |
| 2017-12-31 | RM45.74 Million | +16.00% |
| 2016-12-31 | RM39.43 Million | +1.13% |
| 2015-12-31 | RM38.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PeterLabs Holdings Bhd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 164.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RM36.54 Million | 47.49% |
| Common Stock | RM40.40 Million | 52.51% |
| Total Equity | RM76.94 Million | 100.00% |
PeterLabs Holdings Bhd Competitors by Market Cap
The table below lists competitors of PeterLabs Holdings Bhd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CanAsia Energy Corp.
PINK:CECAF
|
$3.71 Million |
|
Bion Environmental Technologies Inc
OTCQB:BNET
|
$3.71 Million |
|
HOV Services Limited
NSE:HOVS
|
$3.71 Million |
|
GRI Bio Inc.
NASDAQ:GRI
|
$3.71 Million |
|
Attica Publications S.A
AT:ATEK
|
$3.70 Million |
|
BHB Brauholding Bayern-Mitte AG
F:B9B
|
$3.70 Million |
|
Golden Cross Resources Inc
PINK:ZCRMF
|
$3.70 Million |
|
ANEBULO PHARMAC. DL-001
F:214
|
$3.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PeterLabs Holdings Bhd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 75,756,640 to 76,941,050, a change of 1,184,410 (1.6%).
- Net income of 2,285,260 contributed positively to equity growth.
- Dividend payments of 1,100,860 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RM2.29 Million | +2.97% |
| Dividends Paid | RM1.10 Million | -1.43% |
| Other Changes | RM10.00 | +0.0% |
| Total Change | RM- | 1.56% |
Book Value vs Market Value Analysis
This analysis compares PeterLabs Holdings Bhd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.97x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.42x to 0.97x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | RM0.19 | RM0.27 | x |
| 2017-12-31 | RM0.21 | RM0.27 | x |
| 2018-12-31 | RM0.22 | RM0.27 | x |
| 2019-12-31 | RM0.24 | RM0.27 | x |
| 2020-12-31 | RM0.25 | RM0.27 | x |
| 2021-12-31 | RM0.26 | RM0.27 | x |
| 2022-12-31 | RM0.27 | RM0.27 | x |
| 2023-12-31 | RM0.28 | RM0.27 | x |
| 2024-12-31 | RM0.28 | RM0.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PeterLabs Holdings Bhd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.94%
- • Asset Turnover: 2.18x
- • Equity Multiplier: 1.44x
- Recent ROE (2.97%) is below the historical average (6.57%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 8.57% | 4.55% | 1.46x | 1.30x | RM-558.63K |
| 2016 | 8.46% | 3.99% | 1.35x | 1.57x | RM-608.29K |
| 2017 | 8.76% | 4.23% | 1.37x | 1.51x | RM-566.58K |
| 2018 | 7.87% | 4.20% | 1.24x | 1.51x | RM-1.03 Million |
| 2019 | 8.15% | 4.44% | 1.32x | 1.39x | RM-971.73K |
| 2020 | 6.66% | 4.86% | 1.09x | 1.26x | RM-1.95 Million |
| 2021 | 7.57% | 2.98% | 1.65x | 1.54x | RM-1.76 Million |
| 2022 | 4.84% | 2.23% | 1.52x | 1.43x | RM-3.83 Million |
| 2023 | 1.83% | 0.74% | 1.65x | 1.49x | RM-6.19 Million |
| 2024 | 2.97% | 0.94% | 2.18x | 1.44x | RM-5.41 Million |
Industry Comparison
This section compares PeterLabs Holdings Bhd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $194,734,338
- Average return on equity (ROE) among peers: 12.62%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PeterLabs Holdings Bhd (0171) | RM78.60 Million | 8.57% | 0.28x | $3.70 Million |
| Kotra Industries Bhd (0002) | $65.03 Million | 15.36% | 0.20x | $23.04 Million |
| Rhone Ma Holdings Bhd (5278) | $160.98 Million | 7.50% | 0.43x | $4.26 Million |
| Duopharma Biotech Bhd (7148) | $157.87 Million | 18.16% | 0.24x | $132.90 Million |
| YSP Southeast Asia Holding Bhd (7178) | $395.06 Million | 9.45% | 0.32x | $21.44 Million |